X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19311) 19311
Publication (1183) 1183
Book Chapter (75) 75
Book Review (60) 60
Conference Proceeding (41) 41
Dissertation (28) 28
Magazine Article (23) 23
Book / eBook (9) 9
Newspaper Article (5) 5
Data Set (4) 4
Web Resource (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6736) 6736
pyrazine derivatives (4895) 4895
index medicus (4770) 4770
pyrazines - pharmacology (4549) 4549
animals (4081) 4081
male (3944) 3944
bortezomib (3911) 3911
pyrazines - therapeutic use (3004) 3004
female (2915) 2915
middle aged (2037) 2037
pyrazines - administration & dosage (2000) 2000
pyrazine (1848) 1848
oncology (1773) 1773
pyrazines (1767) 1767
aged (1568) 1568
adult (1539) 1539
boronic acids - therapeutic use (1531) 1531
rats (1528) 1528
boronic acids - pharmacology (1481) 1481
multiple myeloma - drug therapy (1472) 1472
mice (1441) 1441
pyrazines - chemistry (1358) 1358
boronic acids - administration & dosage (1238) 1238
pharmacology & pharmacy (1200) 1200
ring closure reactions (1185) 1185
hematology (1170) 1170
cell line, tumor (1078) 1078
pyrazines - adverse effects (1070) 1070
antineoplastic agents - therapeutic use (1003) 1003
treatment outcome (1001) 1001
antineoplastic agents - pharmacology (1000) 1000
apoptosis (979) 979
chemistry, organic (924) 924
multiple myeloma (924) 924
apoptosis - drug effects (905) 905
cancer (897) 897
antineoplastic combined chemotherapy protocols - therapeutic use (882) 882
analysis (866) 866
dose-response relationship, drug (836) 836
biochemistry & molecular biology (821) 821
chemistry, multidisciplinary (821) 821
sitagliptin phosphate (776) 776
chemistry (720) 720
proteasome inhibitors (715) 715
pyrazines - chemical synthesis (711) 711
chemistry, medicinal (705) 705
research (691) 691
chemistry, inorganic & nuclear (688) 688
boronic acids - adverse effects (674) 674
derivatives (642) 642
pharmacology, medicinal chemistry, vaccines, serums (568) 568
molecular structure (563) 563
structure-activity relationship (560) 560
therapy (558) 558
rats, sprague-dawley (554) 554
expression (546) 546
multiple-myeloma (542) 542
diabetes mellitus, type 2 - drug therapy (539) 539
chemistry, physical (525) 525
time factors (523) 523
care and treatment (518) 518
article (517) 517
ligands (509) 509
activation (477) 477
drug therapy, combination (471) 471
protease inhibitors - pharmacology (467) 467
pyrazines - metabolism (467) 467
chemotherapy (461) 461
triazoles - therapeutic use (457) 457
aged, 80 and over (455) 455
multiple myeloma - pathology (455) 455
cell proliferation - drug effects (454) 454
heterocyclic compounds (452) 452
protease inhibitors - therapeutic use (448) 448
dexamethasone - administration & dosage (443) 443
endocrinology & metabolism (432) 432
drug synergism (421) 421
nf-kappa-b (408) 408
cells (407) 407
in vitro techniques (406) 406
thalidomide - analogs & derivatives (406) 406
pyrazines - pharmacokinetics (405) 405
antineoplastic agents - adverse effects (402) 402
pyridine (398) 398
complexes (394) 394
clinical trials as topic (391) 391
food science & technology (389) 389
drug therapy (372) 372
dexamethasone (371) 371
proteins (369) 369
hypoglycemic agents - therapeutic use (366) 366
cell biology (362) 362
proteasome endopeptidase complex - metabolism (359) 359
antineoplastic agents - administration & dosage (352) 352
thalidomide - administration & dosage (347) 347
kinetics (342) 342
models, molecular (335) 335
pyridine derivatives (334) 334
abridged index medicus (332) 332
cells, cultured (332) 332
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18063) 18063
Chinese (502) 502
Japanese (175) 175
German (165) 165
French (156) 156
Italian (147) 147
Russian (60) 60
Polish (48) 48
Spanish (47) 47
Czech (27) 27
Hungarian (15) 15
Dutch (10) 10
Portuguese (10) 10
Danish (7) 7
Swedish (7) 7
Slovak (5) 5
Korean (4) 4
Norwegian (4) 4
Hebrew (3) 3
Finnish (2) 2
Romanian (2) 2
Turkish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article
Chemistry of Heterocyclic Compounds, ISSN 0009-3122, 11/2018, Volume 54, Issue 11, pp. 1075 - 1078
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2015, Volume 93, pp. 330 - 337
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 17, pp. 7773 - 7782
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article